跨性别女性激素治疗及注射后行乳房缩小术一例
本文报告一例跨性别女性在24年激素治疗及乳房等多部位非法硅胶注射后,出现有症状的巨乳症,需行手术乳房缩小。与常规补充性乳房增大不同,该病例提示激素及注射后乳房过度生长需外科减容。
要点
- 跨性别女性激素治疗目标为促进乳房发育等女性化特征。
- 激素治疗后乳房发育不满意者常行补充性乳房增大术。
- 长期激素及非法硅胶注射后可出现有症状巨乳症需乳房缩小。
核心结论
- 跨性别女性长期激素治疗及乳房内非法硅胶注射后,可出现需手术干预的有症状巨乳症。
研究设计与样本
- 个案报道:一例跨性别女性,接受24年激素治疗及多部位(含乳房)非法硅胶注射。
主要发现
- 该患者出现有症状的巨乳症,需行手术乳房缩小。
临床怎么用
- 对长期激素治疗及乳房注射史的跨性别女性,应评估乳房过度生长及相关症状,必要时考虑乳房缩小术。
局限性
- 单一个案报道,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In male-to-female gender transition, individuals request a number of interventions, including hormonal therapy, to promote feminizing characteristics. Estrogen-based medication is prescribed to increase breast development, decrease facial hair, promote feminine adipose tissue deposition, and soften skin. Surgical breast augmentation to supplement unsatisfying breast growth after hormonal therapy is a common and well-studied course of management for such transgender patients. In a departure from convention, the authors present a case of symptomatic macromastia requiring surgical breast reduction in a transgender woman following 24 years of hormonal therapy and illicit silicone injections in multiple areas of her body, including the breasts.
引用
- Margulies IG, Xu H, Kozato A, et al. Breast Reduction Following Hormonal Therapy in a Transgender Female Patient. Ann Plast Surg. 2019. PMID: 31524732. doi:10.1097/SAP.0000000000001855
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。